Clinical Trials Logo
NCT number NCT03497819
Study type Interventional
Source First Affiliated Hospital of Wenzhou Medical Univeristy
Contact
Status Active, not recruiting
Phase Early Phase 1
Start date October 1, 2017
Completion date October 31, 2020

Clinical Trial Summary

Pancreatic cancer patients receive chimeric antigen receptor (CAR) T cells against mesothelin (CARTmeso) or CD19 (CART19) cells administered at 3 days via pancreatic artery infusion or i.v. after preconditioning of cyclophosphamide. Both CART cells are autologous. CARTmeso cells target pancreatic cells which highly express mesothelin, while CART19 cells target tumor-associated B cells expressing cluster of differentiation antigen 19 (CD19) which are mostly immunosuppressive. The investigators hypothesize that this combination therapy may enhance the efficacy of CARTmeso cells in the body. Additionally, a medium dose of cyclophosphamide is used to enhance the engraftment of CART cells.


Clinical Trial Description

This is a single arm, open-label, pilot study to determine the safety and feasibility of combination CARTmeso cells and CART19 cells in patients with pancreatic cancer following lymphodepletion with cyclophosphamide. Both cells contain CAR proteins consisting of a murine-derived single chain antibody fragment (scFv), cluster of differentiation antigen 137 (41BB) co-stimulatory domain and cluster of differentiation antigen 3 zeta chain (CD3ΞΆ) signaling domain transduced by lentivirus


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Recruiting NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients Phase 1/Phase 2
Recruiting NCT02869802 - Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis N/A
Recruiting NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Recruiting NCT02954302 - Proximal Roux-en-y Gastrojejunal Anastomosis on Delayed Gastric Emptying After Pylorus-resecting Pancreaticoduodenectomy N/A
Recruiting NCT02919787 - Norwegian Pancreatic Cancer Trial (NorPACT) - 1 Phase 2/Phase 3
Recruiting NCT02743975 - Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma Phase 1/Phase 2
Recruiting NCT03054987 - Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction N/A
Recruiting NCT02541370 - Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133 Phase 1
Recruiting NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Recruiting NCT02551991 - Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma Phase 1/Phase 2
Active, not recruiting NCT02526017 - Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Terminated NCT02651727 - Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects Phase 1
Not yet recruiting NCT02558868 - Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer Phase 2
Recruiting NCT02424279 - Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic Ladder N/A
Active, not recruiting NCT02245217 - Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients N/A
Terminated NCT02242409 - Study of Gemcitabine and Abraxane for Pancreas Cancer Phase 2
Recruiting NCT02358161 - Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT01939665 - PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma Phase 1/Phase 2
Terminated NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Phase 1